Alimera Sciences Inc

Alimera Sciences — Q2 2016 Earnings Presentation

12 slides from Alimera Sciences's earnings presentation, Aug 4, 2016

  1. Slide 1: Results Conference Call Second Quarter 2016

    Investor Presentation January 2015 Results Conference Call Second Quarter 2016

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, that sales are escalating as practices are being reimbursed regularly and on a timely basis, the opportunity for s

  3. Slide 3: Q2 2016 Highlights

    Q2 2016 Highlights 3 © 2016 Alimera Sciences, All Rights Reserved 3 $2 $9.6M $5.8M Overall Revenue Growth +66% 1Q16 2Q16 EYES TREATED WITH ILUVIEN® TO DATE

  4. Slide 4: United States Significant Growth

    4 © 2016 Alimera Sciences, All Rights Reserved 4 United States Significant Growth Record Quarterly Revenue Driven by growth in new accounts as well as increased penetration into historical accounts Increased acceptance of continuous microsdosing 1Q16 2Q16 US Revenue Growth $7.2M $4.1M +76%

  5. Slide 5: Europe Back on Track

    5 © 2016 Alimera Sciences, All Rights Reserved 5 Europe Back on Track German Unit Volume Increases 5th consecutive quarter 1Q16 2Q16 Europe Revenue Growth $2.3M $1.7M +35% UK Return to Growth 26% growth over Q1 2016 Portuguese Unit Volume Increases 1st half 2016 > all of 2015

  6. Slide 6: Real World Evidence

    Real World Evidence Real world experience consistent with FAME pivotal trials patients Real world results from 550 patients in two studies consistent with FAME pivotal trials “These data demonstrate that in the real world, ILUVIEN® can improve or preserve vision with a side effect profile similar to

  7. Slide 7: FDA Meetings

    FDA Meetings Real world experience mimicking FAME pivotal trials Engaged in discussions with the FDA regarding two potential new indications: • Retinal Vein Occlusion • Non-proliferative diabetic retinopathy

  8. Slide 8: Financial Overview

    Financial Overview Rick Eiswirth, President & CFO

  9. Slide 9: Select Income Statement Data

    9 © 2016 Alimera Sciences, All Rights Reserved 9 Select Income Statement Data ($000’s) Three Months Ended June 30th, 2016 Three Months Ended June 30th, 2015 Revenue $9,557 $5,776 Gross Profit $9,001 $5,400 Gross Margin 94.2% 93.5% Net (Loss) From Operations ($6,449) ($9,800) Net (Loss) Applicable to

  10. Slide 10: Select Balance Sheet Data

    10 © 2016 Alimera Sciences, All Rights Reserved 10 Select Balance Sheet Data ($000’s) As of June 30th, 2016 As of December 31st, 2015 Cash & Cash Equivalents $16,627 $31,075 Total Current Assets $34,664 $45,159 Total Assets $58,766 $70,484 Total Current Liabilities $45,188 $39,933 Total Stockholder’

  11. Slide 11: Closing Remarks

    Closing Remarks Dan Myers, CEO

  12. Slide 12: Results Conference Call Second Quarter 2016

    Investor Presentation January 2015 Results Conference Call Second Quarter 2016

Alimera Sciences — Q2 2016 Earnings Presentation on 6ix